Patents by Inventor Michael Foote

Michael Foote has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20090076009
    Abstract: The invention concerns thiazole derivatives of Formula I or pharmaceutically-acceptable salts thereof, wherein each of R, Ring A, m, R1, R2 and R3 has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in therapy, for example in the treatment of disease mediated by a PI3K enzyme and/or a mTOR kinase.
    Type: Application
    Filed: May 2, 2007
    Publication date: March 19, 2009
    Inventors: Jean-Claude (Retired) Arnould, Kevin Michael Foote, Edward Jolyon Griffen
  • Patent number: 7504408
    Abstract: The invention concerns quinazoline derivatives of Formula (I) wherein each of Z, m, R1, n, R3, Z2 and R14 have any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an anti-invasive or anti-proliferative agent in the containment and/or treatment of solid tumour disease.
    Type: Grant
    Filed: July 4, 2003
    Date of Patent: March 17, 2009
    Assignee: AstraZeneca AB
    Inventors: Laurent Francois Andre Hennequin, Keith Hopkinson Gibson, Kevin Michael Foote
  • Publication number: 20080214495
    Abstract: The invention relates to compounds of formula (I), wherein R1 and R3 are independently selected from carbon and nitrogen; R2 is oxo or thioxo; n is 0, 1 or 2; each R10 is independently selected from hydrogen and C1-3alkyl; R4 and R5 are each selected from carbon and nitrogen, wherein at least one of R4 and R5 is nitrogen; R6 is hydrogen or oxo; R7 is an aliphatic, partially saturated or aromatic carbocyclic ring, said carbocyclic ring having 0, 1 or 2 hetero nitrogen; m is 0, 1 or 2; each R11 is independently selected from hydrogen, hydroxy, oxo, C1-5alkyl, carboxy, hydroxyC1-5alkyl, carboxyC1-5alkyl, C1-5alkoxy-oxoC1-5alkyl, carbamoyl, C1-5alkylcarbamoyl, di (C1-5 alkyl)carbamoyl, carbamoylC1-4alkyl,C1-5alkylcarbamoylC1-4alkyl, di(C1-5alkyl)carbamoylC1-4alkyl, hydroxyC1-5alkylcarbamoyl, C1-5 alkoxyC1-5alkylcarbamoyl, hydroxyC1-5alkylcarbamoylC1-4alkyl, C1-5alkoxyC1-5 alkylcarbamoylC1-4 alkyl, CONR80(CH2)xS(O)pR90, CONH(CH2)qNR100R100, —C1-5 alkyl-Y1, —COOCHR170R180 and —CON R170R180; R8 is a bond, C1-4alkyle
    Type: Application
    Filed: July 5, 2006
    Publication date: September 4, 2008
    Applicant: ASTRAZENECA AB
    Inventors: Christer Alstermark, Kosrat Amin, Kjell Andersson, Yantao Chen, Ulf Fahlander, Kevin Michael Foote, Kenneth Granberg, Daniel Hovdal
  • Publication number: 20080194556
    Abstract: The invention provided a compound of formula (I) for use in the treatment of disease, in particular proliferative diseases such as cancer and for use in the preparation of medicaments for use in the treatment of proliferative diseases; the invention also processes for the preparation of such compounds, as well as pharmaceutical compositions containing them as active ingredient.
    Type: Application
    Filed: May 24, 2006
    Publication date: August 14, 2008
    Applicant: ASTRAZENECA AB
    Inventor: Kevin Michael Foote
  • Patent number: 7408064
    Abstract: The use of a compound of formula (I) in the manufacture of a medicament for the treatment, in a warm-blooded animal, of disorders mediated by the neuropeptide Y5 receptor: wherein: R1, R2, R3 and X1-X6 are as defined within or a pharmaceutically acceptable salt, prodrug or solvate thereof, is described. Pharmaceutical compositions, methods and processes for preparation of compounds of formula (I) are also described.
    Type: Grant
    Filed: September 9, 2002
    Date of Patent: August 5, 2008
    Assignee: AstraZeneca AB
    Inventors: Kevin Michael Foote, Michael Howard Block, Wayne Brailsford
  • Patent number: 7402583
    Abstract: The invention provides a compound of Formula (Ia), or a pharmaceutically acceptable salt thereof, a process for t he preparation of a compound of Formula (1a) and pharmaceutical compositions of a compound of Formula (1a).
    Type: Grant
    Filed: March 14, 2006
    Date of Patent: July 22, 2008
    Assignee: AstrZenca AB
    Inventors: Francis Thomas Boyle, Keith Hopkinson Gibson, Kevin Michael Foote
  • Patent number: 7332492
    Abstract: Compounds of formula (I): wherein: X is a group of formula (B): and R1, R2, R4, n, x, y and z are as defined within are described. Processes for their preparation and their use in the treatment of disorders mediated by the neuropeptide Y5 receptor in a warm-blooded animal, such as a human being, are also described.
    Type: Grant
    Filed: May 12, 2005
    Date of Patent: February 19, 2008
    Assignee: AstraZeneca AB
    Inventors: Michael Howard Block, Kevin Michael Foote
  • Publication number: 20080004302
    Abstract: There is provided a compound of formula (I): processes for the manufacture thereof, pharmaceutical compositions thereof and uses in therapy.
    Type: Application
    Filed: June 27, 2007
    Publication date: January 3, 2008
    Applicant: ASTRAZENECA AB
    Inventors: Maria-Elena Theoclitou, David Buttar, Kevin Michael Foote, Thorsten Nowak, David Alan Rudge, Andrew Peter Thomas
  • Patent number: 7268158
    Abstract: The invention relates to a group of novel thieno-pyrrole compounds of Formula (I): wherein: R1, R2, R3, R4 and R5 are as defined in the specification, which are useful as gonadotrophin releasing hormone antagonists. The invention also relates to pharmaceutical formulations of said compounds, methods of treatment using said compounds and to processes for the preparation of said compounds.
    Type: Grant
    Filed: May 1, 2006
    Date of Patent: September 11, 2007
    Assignee: AstraZeneca AB
    Inventors: Kevin Michael Foote, Zbigniew Matusiak, Alexander Graham Dossetter, Jean Claude Arnould, Maryannick Andree Lamorlette, Benedicte Delouvrie, Annie Hamon
  • Publication number: 20070177288
    Abstract: A gimbal for a gimbaled mirror optical sensor system includes a mirror support rotatable about a first axis along which an optical sensor suite lies, the first axis being spaced apart from a desired pivot point of a variable line of sight, which may be for example a fixed-size window in the outer wall of an aircraft. The gimbal further includes two generally planar mirrors supported by and rotatable with the mirror support. A first mirror is spaced apart from the optical sensor suite along the first axis and is non-orthogonal to the first axis so as to reflect light from a second axis to the optical sensor suite, wherein the second axis sweeps an arcuate path about the first axis upon rotation of the mirror support. A second mirror lies along the second axis so as to follow the arcuate path upon rotation of the mirror support. The second mirror is pivotable so as to reflect light from the variable line of sight to the first mirror along the second axis.
    Type: Application
    Filed: February 1, 2006
    Publication date: August 2, 2007
    Applicant: Textron Systems Corporation
    Inventor: Michael Foote
  • Patent number: 7173135
    Abstract: The invention concerns quinoline derivatives of Formula (I) wherein each of Z1, m, R1, n, R3, Z2 and R14 have any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an anti-invasive or anti-proliferative agent in the containment and/or treatment of solid tumour disease.
    Type: Grant
    Filed: July 4, 2003
    Date of Patent: February 6, 2007
    Assignee: AstraZeneca AB
    Inventors: Laurent Francois Andre Hennequin, Keith Hopkinson Gibson, Kevin Michael Foote
  • Patent number: 7132442
    Abstract: The invention relates to a group of novel thieno-pyrrole compounds of Formula (I): wherein: R1, R2, R3, R4 and R5 are as defined in the specification, which are useful as gonadotrophin releasing hormone antagonists. The invention also relates to pharmaceutical formulations of said compounds, methods of treatment using said compounds and to processes for the preparation of said compounds.
    Type: Grant
    Filed: August 19, 2003
    Date of Patent: November 7, 2006
    Assignee: AstraZeneca AB
    Inventors: Kevin Michael Foote, Zbigniew Matusiak, Alexander Graham Dossetter, Jean Claude Arnould, Maryannick Andree Lamorlette, Benedicte Delouvrie, Annie Hamon
  • Publication number: 20060212161
    Abstract: Certain exemplary embodiments comprise a method comprising a plurality of activities comprising via a graphical editor running on a Human Machine Interface comprising a first embedded operating system, providing a plurality of set points related to a process to a programmable logic controller. The method can comprise, via the programmable logic controller, automatically controlling the process responsive to information received from the graphical editor.
    Type: Application
    Filed: November 28, 2005
    Publication date: September 21, 2006
    Inventors: Ajit Bhat, Emmanuel Bisse, Matthias Erhardt, Michael Foote
  • Patent number: 7067532
    Abstract: The invention provides a compound of Formula (Ia), or a pharmaceutically acceptable salt pro-drug or solvate thereof. The invention also provides a process for the preparation of a compound of Formula (Ia), pharmaceutical compositions of a compound of Formula (Ia) and methods for the treatment or prevention of cancer comprising administering an effective amount of a compound of Formula (Ia).
    Type: Grant
    Filed: October 26, 2001
    Date of Patent: June 27, 2006
    Assignee: AstraZeneca
    Inventors: Francis Thomas Boyle, Keith Hopkinson Gibson, Kevin Michael Foote
  • Patent number: 6967216
    Abstract: Compounds of formula (I): wherein: X is a group of formula (A) or (B): and R1, R2, R3, R4, n, x, y and z are as defined within are described. Processes for their preparation and their use in the treatment of disorders mediated by the neuropeptide Y5 receptor in a warm-blooded animal, such as a human being are also described.
    Type: Grant
    Filed: May 1, 2001
    Date of Patent: November 22, 2005
    Assignee: AstraZeneca AB
    Inventors: Michael Howard Block, Craig Samuel Donald, David Robert Brittain, Kevin Michael Foote
  • Publication number: 20040067999
    Abstract: Compounds of formula (I): are described wherein R1-R6 and m are as defined within. Processes for their preparation and their use as NPY 5 inhibitors is described.
    Type: Application
    Filed: October 10, 2003
    Publication date: April 8, 2004
    Inventors: Michael Howard Block, Kevin Michael Foote, Craig Samuel Donald, Paul Schofield
  • Publication number: 20040029898
    Abstract: The invention provides a compound of Formula (Ia), or a pharmaceutically acceptable salt. prodrug or solvate thereof. The invention also provides a process for the preparation of a compound of Formula (Ia), pharmaceutical compositions of a compound of Formula (Ia) and methods for the treatment or prevention of cancer comprising administering an effective amount of a compound of Formula (Ia).
    Type: Application
    Filed: May 2, 2003
    Publication date: February 12, 2004
    Inventors: Francis Thomas Boyle, Keith Hopkinson Gibson, Kevin Michael Foote
  • Publication number: 20030225097
    Abstract: Compounds of formula (I): 1
    Type: Application
    Filed: November 5, 2002
    Publication date: December 4, 2003
    Inventors: Michael Howard Block, Craig Samuel Donald, David Robert Brittain, Kevin Michael Foote